Appili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia

A review of recent findings suggests that Appili’s biodefense vaccine, ATI-1701, may have a role in preventing tularemia outbreaksHALIFAX, Nova Scotia, May 01, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia, a potentially lethal bacterial inf ...